Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2010 | 1 |
2013 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.
Eur Neuropsychopharmacol. 2014 Feb;24(2):251-61. doi: 10.1016/j.euroneuro.2013.10.007. Epub 2013 Oct 22.
Eur Neuropsychopharmacol. 2014.
PMID: 24239329
This positron emission tomography (PET) study, using [11C]betaCIT-FE, aimed to assess the degree of the dopamine transporter (DAT) occupancy, at constant TE plasma levels, following different oral, multiple doses of TE during totally 8-12 days. ...A si …
This positron emission tomography (PET) study, using [11C]betaCIT-FE, aimed to assess the degree of the dopamine transp …
Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.
Talbot PS, Bradley S, Clarke CP, Babalola KO, Philipp AW, Brown G, McMahon AW, Matthews JC.
Talbot PS, et al.
Neuropsychopharmacology. 2010 Feb;35(3):741-51. doi: 10.1038/npp.2009.182. Epub 2009 Nov 4.
Neuropsychopharmacology. 2010.
PMID: 19890256
Free PMC article.
Clinical Trial.
Sibutramine is a centrally acting monoamine reuptake inhibitor prescribed as an appetite suppressant in the management of obesity. Its effects are mostly attributable to serotonin and norepinephrine transporter (SERT and NET, respectively) inhibition by its potent m …
Sibutramine is a centrally acting monoamine reuptake inhibitor prescribed as an appetite suppressant in the management of obesity. It …
Item in Clipboard
Cite
Cite